Below is the list of biopharmaceuticals being developed by Bionovis together with Janssen and Merck and the biological products fully developed by Bionovis in-house:
Trastuzumab:
Trasuzumab is indicated for the treatment of initial breast cancer, metastatic breast cancer and advanced gastric cancer.
Bevacizumab:
Bevacizumab is indicated for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic renal cell carcinoma and metastatic breast cancer.
Etanercept:
Etanercept is indicated for the treatment of autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
Rituximab:
Rituximab is indicated for the treatment of non-Hodgkin lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and granulomatosis with Polyangiitis.
Adalimumab:
Adalimumab is indicated for the treatment of autoimmune diseases such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
BNV-003:
Biological medicine indicated for the treatment of colorectal cancer and squamous cell carcinoma of head and neck.
BNV-004:
Biological medicine indicated for the treatment of multiple sclerosis.
BNV-005 (in-house development):
Biological medicine indicated for the treatment of autoimmune diseases.
BNV-006 (in-house development):
Biological medicine indicated for the treatment of autoimmune diseases.